Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Outlook Therapeutics, Inc. Common Stock (OTLK)

Biological Products, (no Disgnostic Substances)

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

485 ROUTE 1 SOUTH, BUILDING F, SUITE 320
ISELIN, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/13/2016

Market Cap

184,040,568

Shares Outstanding

260,260,000

Weighted SO

260,257,517

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

CKPT --.--%

MBIO --.--%

RVPH --.--%

FBIOP --.--%

KOD --.--%

OCUP --.--%

PLX --.--%

EYPT --.--%

SLS --.--%

Beta

0.7160

Last Div

0.0000

Range

4.0-29.2

Chg

0.1000

Avg Vol

217159

Mkt Cap

184040568

Exch

NASDAQ

Country

US

Phone

609 619 3990

DCF Diff

8.7224

DCF

-0.9724

Div Yield

0.0000

P/S

0.0000

EV Multiple

-2.8229

P/FV

-2.1597

Div Yield %

0.0000

P/E

-1.9214

PEG

-0.0793

Payout

0.0000

Current Ratio

1.0720

Quick Ratio

1.0720

Cash Ratio

0.7526

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

21049.8308

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-29.7438

ROA

-1.9971

ROE

1.4656

ROCE

-13.5051

NI/EBT

1.0000

EBT/EBIT

1.5346

EBIT/Rev

0.0000

Debt Ratio

5530.2169

D/E

-3112.4251

LT Debt/Cap

1.0003

Total Debt/Cap

1.0003

Int Coverage

0.0000

CF/Debt

-0.0002

Equity Multi

-0.5628

Rec Turnover

0.0000

Pay Turnover

0.0173

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-2.7792

FCF/Share

-2.7792

Cash/Share

1.3788

OCF/Sales

0.0000

FCF/OCF

1.0000

CF Coverage

-0.0002

ST Coverage

-1.9885

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

-2.1597

P/B

-2.1597

P/S

0.0000

P/E

-1.9214

P/FCF

-2.8510

P/OCF

-2.7993

P/CF

-2.7993

PEG

-0.0793

P/S

0.0000

EV Multiple

-2.8229

P/FV

-2.1597

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 29, 09:20 Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday GlobeNewswire Inc. Dec 22, 08:05 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU PennyStocks Nov 27, 12:17 Best Penny Stocks To Buy Today? 3 To Watch This Week PennyStocks Nov 07, 14:12 Invest In Penny Stocks? Is It Worth It & 4 To Watch Now PennyStocks Nov 03, 17:09 3 Penny Stocks To Buy According To Analysts, Targets Up To 365% PennyStocks Nov 03, 17:09 3 Penny Stocks To Buy According To Analysts, Targets Up To 365% Benzinga Nov 03, 15:25 This Analyst Upgrades Vision Disorder-Focused Outlook Therapeutics' Prospects After FDA Agreement Despite Investor Concerns PennyStocks Nov 01, 14:11 5 Most Active Penny Stocks Today & Why They’re Moving Now

Revenue Product Segmentation